Terms: = Lung cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2
65 results:
1. Malignant peritoneal mesotheliomas of rats induced by multiwalled carbon nanotubes and amosite asbestos: transcriptome and epigenetic profiles.
Reamon-Buettner SM; Rittinghausen S; Klauke A; Hiemisch A; Ziemann C
Part Fibre Toxicol; 2024 Jan; 21(1):3. PubMed ID: 38297314
[TBL] [Abstract] [Full Text] [Related]
2. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
3. Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease.
Harris KM; Preiss L; Varughese T; Bauer A; Calhoun CL; Treadwell M; Masese R; Hankins JS; Hussain FA; Glassberg J; Melvin CL; Gibson R; King AA;
JAMA Netw Open; 2023 May; 6(5):e2314070. PubMed ID: 37200033
[TBL] [Abstract] [Full Text] [Related]
4. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell lung cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract] [Full Text] [Related]
5. Special issue "The advance of solid tumor research in China": fgfr4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
Gao G; Cui L; Zhou F; Jiang T; Wang W; Mao S; Wu F; Jiang F; Zhang B; Bei T; Xie W; Zhang C; Zhang H; Gao C; Zhao X; Bai Y; Zhou C; Ren S
Int J Cancer; 2023 Jan; 152(1):79-89. PubMed ID: 36062503
[TBL] [Abstract] [Full Text] [Related]
6. Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.
Sitthideatphaiboon P; Teerapakpinyo C; Korphaisarn K; Leelayuwatanakul N; Pornpatrananrak N; Poungvarin N; Chantranuwat P; Shuangshoti S; Aporntewan C; Chintanapakdee W; Sriuranpong V; Vinayanuwattikun C
Sci Rep; 2022 Feb; 12(1):2167. PubMed ID: 35140316
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Analysis of Different Metastatic Patterns in Invasive Intraductal Papillary Mucinous Neoplasm: A Surveillance, Epidemiology, and End Results Database Analysis.
Zhou C; Liu Z; Zhou Y; Ren D; Liu K; Qin G; Zhang H; Liang X; Gou S; Wu H
Can J Gastroenterol Hepatol; 2021; 2021():4350417. PubMed ID: 35047460
[TBL] [Abstract] [Full Text] [Related]
8. Development of a prognostic signature of patients with esophagus adenocarcinoma by using immune-related genes.
Zhang X; Yang L; Kong M; Ma J; Wei Y
BMC Bioinformatics; 2021 Nov; 22(1):536. PubMed ID: 34724890
[TBL] [Abstract] [Full Text] [Related]
9. Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma.
Deng Z; Cui L; Li P; Ren N; Zhong Z; Tang Z; Wang L; Gong J; Cheng H; Guan Y; Yi X; Xia X; Zhou R; He Z
Cell Death Dis; 2021 Oct; 12(10):935. PubMed ID: 34642306
[TBL] [Abstract] [Full Text] [Related]
10. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
[TBL] [Abstract] [Full Text] [Related]
11. Development of nomogram based on immune-related gene fgfr4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
Wang L; Ren Z; Yu B; Tang J
J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
[TBL] [Abstract] [Full Text] [Related]
12. fgfr4 Gene Polymorphism Reduces the Risk of Distant Metastasis in lung Adenocarcinoma in Taiwan.
Li JP; Huang HC; Yang PJ; Chang CY; Chao YH; Tsao TC; Huang H; Hung YC; Hsieh MJ; Yang SF
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32781755
[TBL] [Abstract] [Full Text] [Related]
13. fgfr4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S; Thennavan A; East MP; Parker JS; Cejalvo JM; Garay JP; Hollern DP; He X; Mott KR; Galván P; Fan C; Selitsky SR; Coffey AR; Marron D; Brasó-Maristany F; Burgués O; Albanell J; Rojo F; Lluch A; de Dueñas EM; Rosen JM; Johnson GL; Carey LA; Prat A; Perou CM
J Clin Invest; 2020 Sep; 130(9):4871-4887. PubMed ID: 32573490
[TBL] [Abstract] [Full Text] [Related]
14. FGFR1 and fgfr4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract] [Full Text] [Related]
15. Enhanced autocrine FGF19/fgfr4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104.
Li F; Li Z; Han Q; Cheng Y; Ji W; Yang Y; Lu S; Xia W
Oncogene; 2020 Apr; 39(17):3507-3521. PubMed ID: 32111983
[TBL] [Abstract] [Full Text] [Related]
16. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
[TBL] [Abstract] [Full Text] [Related]
17. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract] [Full Text] [Related]
18. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
[TBL] [Abstract] [Full Text] [Related]
19. A patent review of fgfr4 selective inhibition in cancer (2007-2018).
Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
[TBL] [Abstract] [Full Text] [Related]
20. fgfr4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.
Quintanal-Villalonga A; Molina-Pinelo S; Yagüe P; Marrugal Á; Ojeda-Márquez L; Suarez R; Ponce-Aix S; Enguita AB; Carnero A; Ferrer I; Paz-Ares L
Lung Cancer; 2019 May; 131():112-121. PubMed ID: 31027687
[TBL] [Abstract] [Full Text] [Related]
[Next]